Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05209295 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05209295 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 2 participants.
The verdict
NCT05209295, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
Interventions
- DRUG Onureg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2025-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05209295
The ClinicalTrials.gov registry entry for NCT05209295 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Onureg is the first listed.
NCT05209295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05209295 about?
NCT05209295 is a clinical study titled "A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies". The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
What is the current status of trial NCT05209295?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2024-07-12. Estimated completion is 2025-04-20.
What interventions are being tested in trial NCT05209295?
The interventions under investigation include: Onureg (DRUG).
Who is sponsoring clinical trial NCT05209295?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.